Literature DB >> 10221759

Dopamine D3 receptor agonists produce similar decreases in body temperature and locomotor activity in D3 knock-out and wild-type mice.

D Boulay1, R Depoortere, W Rostene, G Perrault, D J Sanger.   

Abstract

The function of the dopamine (DA) D3 receptor, a member of the D2-like family, has not been firmly established. It has been reported that the potency of DA receptor agonists in producing hypothermia and hypolocomotion in rodents correlates more strongly with the in vitro affinity for, or potency (mitogenesis test) at the D3 than the D2 subtype. In order to investigate further the role of D3 receptors in hypothermia and hypolocomotion, we tested the effects of ip administration of three DA receptor agonists reported to be selective for the D3 receptor subtype (7-OH-DPAT, quinelorane and PD 128907) on core temperature and spontaneous locomotor activity in homozygous (D3-/-), heterozygous (D3+/-) mutant and wild-type (D3+/+) mice. Quinelorane (0.003-0.3 mg/kg), PD 128907 (1-10 mg/kg) and 7-OH-DPAT (0.1-3 mg/kg) induced hypothermia and decreased locomotion to a similar extent in the three genotypes. Additionally, the putatively selective DA D3 receptor antagonist PNU 99194A (3-20 mg/kg i.p.) increased locomotor activity in habituated mice and reversed the hypothermia induced by 30 microg/kg of quinelorane, with no apparent difference between D3-/-, D3+/- and D3+/+ genotypes. The spontaneous level of locomotor activity of mutants (D3-/- or D3+/-) was found to be either at, below, or above that of controls, with no consistent trend between different batches of mice. These results show that the presence of DA D3 receptors is not necessary for the expression of these effects induced by the three agonists or the antagonist supposedly selective for the D3 receptor subtype. This raises the question of the involvement of the D3 receptor in these behavioural effects and the issue of the in vivo selectivity of these four compounds for the D3 receptor subtype. Alternatively, possible adaptive mechanisms taking place in D3-/- mice might have compensated for the absence of DA D3 receptors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10221759     DOI: 10.1016/s0028-3908(98)00213-5

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  24 in total

1.  Essential conservation of D1 mutant phenotype at the level of individual topographies of behaviour in mice lacking both D1 and D3 dopamine receptors.

Authors:  John Y F Wong; Jeremiah J Clifford; Jim S Massalas; Anthony Kinsella; John L Waddington; John Drago
Journal:  Psychopharmacology (Berl)       Date:  2003-03-22       Impact factor: 4.530

Review 2.  Dopamine D3 receptor: A neglected participant in Parkinson Disease pathogenesis and treatment?

Authors:  Pengfei Yang; Joel S Perlmutter; Tammie L S Benzinger; John C Morris; Jinbin Xu
Journal:  Ageing Res Rev       Date:  2019-11-22       Impact factor: 10.895

Review 3.  Phenotypic studies on dopamine receptor subtype and associated signal transduction mutants: insights and challenges from 10 years at the psychopharmacology-molecular biology interface.

Authors:  John L Waddington; Colm O'Tuathaigh; Gerard O'Sullivan; Katsunori Tomiyama; Noriaki Koshikawa; David T Croke
Journal:  Psychopharmacology (Berl)       Date:  2005-09-29       Impact factor: 4.530

4.  Relative expression of D3 dopamine receptor and alternative splice variant D3nf mRNA in high and low responders to novelty.

Authors:  Laurel M Pritchard; Aaron D Logue; Benjamin C Taylor; Rebecca Ahlbrand; Jeffrey A Welge; Yang Tang; Frank R Sharp; Neil M Richtand
Journal:  Brain Res Bull       Date:  2006-07-13       Impact factor: 4.077

Review 5.  The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence.

Authors:  Christian A Heidbreder; Eliot L Gardner; Zheng-Xiong Xi; Panayotis K Thanos; Manolo Mugnaini; Jim J Hagan; Charles R Ashby
Journal:  Brain Res Brain Res Rev       Date:  2005-07

6.  Selective D2 and D3 receptor antagonists oppositely modulate cocaine responses in mice via distinct postsynaptic mechanisms in nucleus accumbens.

Authors:  Daniel F Manvich; Alyssa K Petko; Rachel C Branco; Stephanie L Foster; Kirsten A Porter-Stransky; Kristen A Stout; Amy H Newman; Gary W Miller; Carlos A Paladini; David Weinshenker
Journal:  Neuropsychopharmacology       Date:  2019-03-16       Impact factor: 7.853

7.  Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior.

Authors:  Gregory T Collins; Jeffrey M Witkin; Amy H Newman; Kjell A Svensson; Peter Grundt; Jianjing Cao; James H Woods
Journal:  J Pharmacol Exp Ther       Date:  2005-04-15       Impact factor: 4.030

8.  Yawning and locomotor behavior induced by dopamine receptor agonists in mice and rats.

Authors:  Su-Min Li; Gregory T Collins; Noel M Paul; Peter Grundt; Amy H Newman; Ming Xu; David K Grandy; James H Woods; Jonathan L Katz
Journal:  Behav Pharmacol       Date:  2010-05       Impact factor: 2.293

9.  Divergent effect of the selective D3 receptor agonist pd-128,907 on locomotor activity in Roman high- and low-avoidance rats: relationship to NGFI-A gene expression in the Calleja islands.

Authors:  Marc Guitart-Masip; Björn Johansson; Albert Fernández-Teruel; Adolf Tobeña; Lydia Giménez-Llort
Journal:  Psychopharmacology (Berl)       Date:  2007-10-19       Impact factor: 4.530

10.  Yawning and hypothermia in rats: effects of dopamine D3 and D2 agonists and antagonists.

Authors:  Gregory T Collins; Amy Hauck Newman; Peter Grundt; Kenner C Rice; Stephen M Husbands; Cédric Chauvignac; Jianyong Chen; Shaomeng Wang; James H Woods
Journal:  Psychopharmacology (Berl)       Date:  2007-03-29       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.